Resources available through this program:

  • Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy
    This article discusses the complex interplay among the addictive disease, acute pain management, and the treatment of patients receiving opioid agonist therapy (OAT). Four common misconceptions are also discussed.
  • Addiction Behaviors Checklist (ABC)
    The Addiction Behavior Checklist (ABC) is a brief screening instrument with 20 behavioral questions that physicians deliver as an interview; it is designed to track problematic behaviors of addiction.
  • Alcoholics Anonymous
    Alcoholics Anonymous® is a fellowship of men and women who share their experience, strength and hope with each other that they may solve their common problem and help others to recover from alcoholism. The only requirement for membership is a desire to stop drinking. There are no dues or fees for AA membership; we are self-supporting through our own contributions. AA is not allied with any sect, denomination, politics, organization or institution; does not wish to engage in any controversy, neither endorses nor opposes any causes. Our primary purpose is to stay sober and help other alcoholics to achieve sobriety (From their Website).
  • American Association for the Treatment of Opioid Dependence
    The American Association for the Treatment of Opioid Dependence (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive methadone treatment services throughout the United States. (From Their Website)
  • American Society of Addiction Medicine (ASAM)
    The American Society of Addiction Medicine (ASAM) is an organization dedicated to increase access to and improve the quality of addiction treatment, educate physicians (including medical students and osteopathic students), other health care providers and the public, to support research and prevention, to promote the appropriate role of the physician in the care of patients with addiction, and to establish addiction medicine as a specialty (From their Website).
  • An Interview with Kathleen T. Brady, M.D., Ph.D.
    Dr. Kathleen Brady is a professor of psychiatry at the Medical School of the University South Carolina, and an expert in addiction and co-occurring psychiatric disorders. In this video, she discusses how underlying disorders like anxiety, depression or trauma can lead to addiction or relapse, stressing the necessity of treating these mental disorders and addiction simultaneously.
  • APA Practice Guidelines for the Treatment of Patients with Substance Use Disorders
    The American Psychiatric Association has released practice guidelines and resources for the treatment of patients with substance use disorders.
  • ASAM Patient Placement Criteria
    The ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, Second Edition-Revised (Mee-Lee et al., 2001) lists the 5 basic levels of care available for adult substance users. These levels of care range from Early Intervention (for at-risk individuals) to Medically Managed Intensive Inpatient Treatment (for patients with severe disorders who require around-the-clock care). The Patient Placement Criteria classifies opioid maintenance therapy as a Level I treatment since it is most often conducted in outpatient settings.
  • Assessing Patients With Pain
    A list of clinical features and their frequency in both patients with pain and patients who are addicted to opioids.
  • Baraclude® (entecavir)
    This is the website for the drug Baraclude®, one of the five types of antiviral drugs approved to treat individuals with chronic hepatitis B.
  • Buprenorphine Maintenance Treatment Information for Family Members
    Family members of patients who have been prescribed buprenorphine for treatment of addiction often have questions about this treatment. This handout will provide answers to their questions.
  • Buprenorphine Treatment Agreement
    Buprenorphine Treatment Agreement - handout for patients.
  • CRAFFT: Brief Screening Tool for Adolescents
    THE CRAFFT is a screening instrument used to detect alcohol and other drug abuse.
  • DATA 2000 Requirements for Providing or Prescribing Schedule III, IV, and V Narcotic drugs for Detoxification and Maintenance Therapy
    Lists the qualifying criteria for primary care physicians to administer buprenorphine.
  • DEA Policy Statement: Dispensing Controlled Substances for the Treatment of Pain
    This document provides an elaboration of the legal requirements and agency policy related to dispensing controlled substances for the treatment of pain.
  • Depression and Bipolar Support Alliance
    This website aims to improve the lives of those living with mood disorders, and to provide information on bipolar disorder. Sections of the website include signs and symptoms, just diagnosed, recovery steps, and helping a loved one.
  • Drug Abuse Screening Test (DAST-10)
    The Drug Abuse Screening Test (DAST) is a drug use questionnaire that assesses problems and consequences related to drug (including prescription) misuse. Scoring and Interpretation information is provided at the end of this questionnaire.
  • DSM-IV Criteria for Opioid Withdrawal
    Lists the DSM-IV Criteria for Opioid Withdrawal.
  • FAQs for Patients: Suboxone
    Frequently asked questions about Suboxone.
  • Hepatitis C: MedlinePlus
    This page describes the basics of hepatitis C and provides links to many helpful resources, both for patients and healthcare professionals.
  • Hepatitis Foundation International
    This website addresses the rising tide of preventable liver diseases, including hepatitis, fatty liver, and drug use and abuse and alcohol-related liver disease. The site offers information for people living with hepatitis, such as preventing hepatitis, diagnosis and treatment, and how to live with hepatitis. There are also news and research, education, and support sections.
  • How Buprenorphine Works
    One-page handout that provides graphics and a description of the pharmacology of buprenorphine in layman's terms.
  • Information Brief: Prescription Drug Abuse and Youth
    Common prescription drugs of abuse and how youth acquire them are covered in this information brief.
  • Initial Patient Contact About Buprenorphine
    Initial Patient Contact about Buprenorphine Checklist
  • Intervention: Video
    This three-minute video follows a young woman reflecting on her past dependence on heroin (follows a brief sponsored ad).
  • Intron A® (Interferon-alpha)
    This is the website for the drug Intron A®, one of the five types of antiviral drugs approved to treat individuals with chronic hepatitis B.
  • Lamivudine
    This is the website for the lamivudine, one of the five types of antiviral drugs approved to treat individuals with chronic hepatitis B.
  • Management of Hepatitis C: 2002
    Current NIH consensus statement on management of Hepatitis C. Also presents background information on the history and epidemiology of the disease.
  • Model Policy for the Use of Controlled Substances for the Treatment of Pain
    The Federation of State Medical Boards guidelines to state boards for developing their own policy on use of opioid analgesics in treating chronic pain.
  • Modified Objective Opiate Withdrawal Scale
    A worksheet from the AAAP that allows you to score a patient's types of opioid withdrawal symptoms twice a day for the 2 induction days
  • Narcotics Anonymous World Services
    This is the website of Narcotics Anonymous, an international, community-based association of recovering drug addicts.
  • National Alliance on Mental Illness
    This is the website for the NAMI, a grassroots mental health advocacy organization. This website includes information on mental illnesses, medications, support and programs, online communities, legislation, and local resources.
  • New Attitudes & Strategies: A Comprehensive Approach to Preventing Blood-Borne Infections Among IDUs
    This brochure contains principles for providers to use as a guideline for care when working with injection drug users.
  • NIMH Bipolar Disorder
    This web page describes bipolar disorder, and gives examples of symptoms, common co-existing illnesses, risk factors. It offers information on diagnosis and treatment, and provides further information on finding help and other resources.
  • Opiate Addiction: A New Medication
    This short video discusses buprenorphine and follows two individuals as they seek treatment for their opioid use disorder.
  • Opioid Misuse, Abuse, and Addiction (includes CAGE-AID and SISAP tools)
    Information about Opioid Misuse, Abuse, and Addiction. It also provides the SISAP and CAGE-AID screening tool questionnaires.
  • Pain Management in Patients Maintained on Buprenorphine
    This powerpoint presentation of the treatment of acute and chronic pain patients presents several different aspects of pain care, including general points regarding pain treatments, acute pain in buprenorphine maintained patients, and the differences between acute and chronic pain.
  • Patient Information and Consent to Treatment with Buprenorphine
    Sample of a patient information and consent to treatment with buprenorphine.
  • Pegaysys® (Pegylated Interferon)
    This is the website for the drug Pegaysys®, one of the five types of antiviral drugs approved to treat individuals with chronic hepatitis B.
  • Practitioner's Manual An Informational Outline of the Controlled Substances Act
    This manual has been prepared by the Drug Enforcement Administration, Office of Diversion Control, to assist practitioners (physicians, dentists, veterinarians, and other registrants authorized to prescribe, dispense, and administer controlled substances) in their understanding of the Federal Controlled Substances Act and its implementing regulations as they pertain to the practitioner’s profession.
  • Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings
    This are the latest CDC recommendations for HIV treatment.
  • SAMHSA's Information about Buprenorphine and Training
    A site for physicians, researchers, pharmacists, nurses, and counselors to learn more about buprenorphine as a medication for opioid addiction treatment.
  • SAMHSA's Mental Health Information Center
    This website provides information on mental health services, with a "mental health topics" section, a newsroom, and sections devoted to publications and resources.
  • Schedule of Opioids
    A table representing the table of opioids
  • Summary of the HIPAA Privacy Rule
    This is a summary of key elements of the Privacy Rule including who is covered, what information is protected, and how protected health information can be used and disclosed. Because it is an overview of the Privacy Rule, it does not address every detail of each provision.
  • The Consequences of Illegal Drug Use
    This webpage provides statistics on the economic, social, and medical consequences of illegal drug use in the United States.
  • The Mood Disorder Questionnaire
    The mood disorder questionnaire consists of five yes or no questions to be completed by the patient. The MDQ was developed by a team of psychiatrists, researchers and consumer advocates to address a critical need for timely and accurate diagnosis of bipolar disorder, which can be fatal if left untreated. The questionnaire takes about five minutes to complete, and can provide important insights into diagnosis and treatment.
  • The Search for Treatment: A Challenging Journey
    This video interview explores the challenges of addiction for both the addict and their family members. Topics discussed include finding the right treatment for an individual, and what questions should one ask a treatment provider? In this film, leading experts answer these questions and offer knowledge on evidence-based treatments (those proven effective). They detail the first steps to take to find the right program for an addict, ideally a combination of behavioral therapy and medication.
  • TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
    This Treatment Improvement Protocol (TIP), Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus‐ and evidence‐based treatment guidance for the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide physicians with information they can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. These guidelines address the pharmacology and physiology of opioids, opioid addiction, and treatment with buprenorphine; describe patient assessment and the choice of opioid addiction treatment options; provide detailed treatment protocols for opioid withdrawal and maintenance therapy with buprenorphine; and include information on the treatment of special populations, e.g., pregnant women, adolescents, and polysubstance users. This TIP represents another step by the Center for Substance Abuse Treatment (CSAT) toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States. (From Their Website)
  • TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
    This Treatment Improvement Protocol (TIP) is a guide to medication-assisted treatment for opioid addiction (MAT) in opioid treatment programs (OTPs). Compared with MAT in other settings, such as physicians' offices or detoxification centers, treatment in OTPs provides a more comprehensive, individually tailored program of medication therapy integrated with psychosocial and medical treatment and support services that address most factors affecting each patient. Treatment in OTPs also can include detoxification from illicit opioids and medically supervised withdrawal from maintenance medications. This TIP combines and updates TIP 1 (State Methadone Treatment Guidelines, published in 1993), TIP 10 (Assessment and Treatment of Cocaine-Abusing Methadone-Maintained Patients, published in 1994), TIP 20 (Matching Treatment to Patient Needs in Opioid Substitution Therapy, published in 1995), and TIP 22 (LAAM in the Treatment of Opiate Addiction, published in 1995). It incorporates the many changes in MAT that have occurred since the publication of TIP 1, primarily as they are reflected in OTPs, and discusses the challenges that remain. (From Their Website)
  • Trends in Heroin Use: Age
    Describes recent trends in heroin use by age.
  • Trends in Heroin Use: Route of Administration
    Describes recent trends in heroin use by route of administration.
  • Trends in Heroin Use: Sex
    Describes recent trends in heroin use by sex.
  • Trends in Prescription Drug Misuse: Age
    Describes recent trends in prescription drug misuse by age.
  • Trends in Prescription Drug Misuse: Sex
    Describes recent trends in prescription drug misuse by sex.
  • Understanding Opioid Dependence
    A patient handout that explains opioid dependence to the abuser.
  • Video: Opioid Addiction, Understanding Replacement Therapy
    Watch in a video as a support group receives psychoeducation on the neurobiology of opioids. Summary from their Website: An informal lecture by Scott Farnum, Administrator, Acadia Hospital in Bangor, Maine. At Acadia's model drug treatment program, Farnum discusses the different types of opioids and their effects on the brain. Farnum's lecture clearly explains why replacement therapy is an effective way to recover from opioid addiction. While replacement therapy medications such as methadone and bupenorphine (Suboxone) are not magic bullets, they can help alleviate cravings and other withdrawal symptoms that often lead to relapse.
  • Video: The Adolescent Addict
    A video of interviews with providers and adolescents about substance abuse in adolescents.
  • Viral Hepatitis
    Provides information and resources on Hepatitis A, B, C, D, and E.